Syncore Biotechnology Co.,Ltd Reports Earnings Results for the Third Quarter Ended September 30, 2020
November 09, 2020 at 01:44 pm EST
Share
SynCore Biotechnology Co.,Ltd announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced sales was TWD 3.932 million compared to TWD 2.039 million a year ago. Operating loss was TWD 100.151 million compared to TWD 112.738 million a year ago. Net loss was TWD 101.990 million compared to TWD 110.785 million a year ago. Basic loss per share was TWD 0.96 compared to TWD 1.22 a year ago. For the nine months, sales was TWD 7.672 million compared to TWD 10.841 million a year ago. Operating loss was TWD 294.698 million compared to TWD 300.773 million a year ago. Net loss was TWD 296.260 million compared to TWD 296.367 million a year ago. Basic loss per share was TWD 2.87 compared to TWD 3.38 a year ago.
SynCore Biotechnology Co.,Ltd is a Taiwan-based company principally engaged in the research, development, production and sales of therapeutic drugs. The Company's main product is SB03 Veregen. The Company is also involved in research, development and clinical trials of the injection-type anticancer drug, SB01 and the oral anticancer drug, SB01. The Company distributes its products mainly in domestic market.